VERU-111 + Enzalutamide, Abiraterone
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Castration-resistant Prostate Cancer
Conditions
Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer
Trial Timeline
Jun 24, 2021 → May 4, 2023
NCT ID
NCT04844749About VERU-111 + Enzalutamide, Abiraterone
VERU-111 + Enzalutamide, Abiraterone is a phase 3 stage product being developed by Veru for Metastatic Castration-resistant Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT04844749. Target conditions include Metastatic Castration-resistant Prostate Cancer, Androgen Resistant Prostatic Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Castration-resistant Prostate Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04844749 | Phase 3 | Terminated |
Competing Products
20 competing products in Metastatic Castration-resistant Prostate Cancer